Teva buys stake in Rexahn to access anticancer compound
This article was originally published in Scrip
Executive Summary
Rexahn Pharmaceuticals and Teva Pharmaceutical Industries have closed their licensing and investment deal for the preclinical anticancer compound RX-3117.